Details

Autor(en) / Beteiligte

• Liu, Limin
• Zhang, Xingxia
• Qiu, Huiying
• Tang, Xiaowen
• Han, Yue
• Fu, Chengcheng
• Jin, Zhengming
• Zhu, Mingqing
• Miao, Miao
• Wu, Depei

Titel

HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate/high-risk acute myeloid leukemia

Ist Teil von

• Annals of hematology, 2019-05, Vol.98 (5), p.1249-1257

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2019

Quelle

SpringerLink

Beschreibungen/Notizen

• HLA-mismatched stem cell microtransplantation is a new form of transplantation reported in recent years. We compared 59 patients undergoing microtransplantation to 66 patients undergoing HLA-matched sibling donor (MSD) transplantation at the same period from April 2012 to December 2016, who all suffered from intermediate/high-risk acute myelogenous leukemia (AML) in first complete remission (CR1). The estimated overall survival (OS) at 2 years was 74.1% ± 6.2% and 34.3% ± 7.9% in MSD and microtransplantation group, respectively ( P  = 0.001). The estimated leukemia-free survival (LFS) at 2 years was 73.3% ± 6.1% in the MSD group and 31.6% ± 7.6% in the microtransplantation group ( P  = 0.000). The 2-year cumulative incidence of relapse was 17.6% and 62.3% in the MSD and microtransplantation groups, respectively ( P  < 0.0001). The 2-year cumulative incidence of nonrelapse mortality was 10.9% in MSD group and 4.2% in the microtransplantation group ( P  = 0.251). Hematopoietic recovery time was shorter in the microtransplantation group than in the MSD group ( P  < 0.05). The infection rate was higher in the MSD group than in the microtransplantation group ( P  = 0.012). The preliminary results suggested that OS and LFS of microtransplantation were inferior to MSD transplantation for intermediate/high-risk AML in CR1.